SARS-CoV-2 Variants and Vaccines.
Philip R Krause 
;
Thomas RFleming;
Ira MLongini;
RichardPeto;
SylvieBriand;
David LHeymann;
ValerieBeral;
Matthew DSnape;
HelenRees;
Alba-MariaRopero;
+11 more...
Ran DBalicer;
Jakob PCramer;
CésarMuñoz-Fontela;
MarionGruber;
RogerioGaspar;
Jerome ASingh;
KantaSubbarao;
Maria DVan Kerkhove;
SoumyaSwaminathan;
Michael JRyan;
Ana-MariaHenao-Restrepo;
(2021)
SARS-CoV-2 Variants and Vaccines.
New England Journal of Medicine, 385 (2).
pp. 179-186.
ISSN 0028-4793
DOI: 10.1056/NEJMsr2105280
;
Thomas RFleming;
Ira MLongini;
RichardPeto;
SylvieBriand;
David LHeymann;
ValerieBeral;
Matthew DSnape;
HelenRees;
Alba-MariaRopero;
+11 more...
Ran DBalicer;
Jakob PCramer;
CésarMuñoz-Fontela;
MarionGruber;
RogerioGaspar;
Jerome ASingh;
KantaSubbarao;
Maria DVan Kerkhove;
SoumyaSwaminathan;
Michael JRyan;
Ana-MariaHenao-Restrepo;
(2021)
SARS-CoV-2 Variants and Vaccines.
New England Journal of Medicine, 385 (2).
pp. 179-186.
ISSN 0028-4793
DOI: 10.1056/NEJMsr2105280
Viral variants of concern may emerge with dangerous resistance to the immunity generated by the current vaccines to prevent coronavirus disease 2019 (Covid-19). Moreover, if some variants of concern have increased transmissibility or virulence, the importance of efficient public health measures and vaccination programs will increase. The global response must be both timely and science based.
-
picture_as_pdf - Krause-etal-2021-SARS-CoV-2-Variants-and-Vaccines.pdf
-
subject - Published Version
-
copyright - Available under Copyright the publishers
Explore Further
Read more research from the creator(s):
Find work associated with the faculties and division(s):
Find work associated with the research centre(s):
Find work from this publication: